EP2885054A1 - Herbal preparation for stimulation of hair growth, control of hair fall, dandruff and infections thereof using ageratum spp. - Google Patents
Herbal preparation for stimulation of hair growth, control of hair fall, dandruff and infections thereof using ageratum spp.Info
- Publication number
- EP2885054A1 EP2885054A1 EP13879457.3A EP13879457A EP2885054A1 EP 2885054 A1 EP2885054 A1 EP 2885054A1 EP 13879457 A EP13879457 A EP 13879457A EP 2885054 A1 EP2885054 A1 EP 2885054A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hair
- herbal
- acid
- herbal extract
- ageratum spp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 39
- 230000003779 hair growth Effects 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 208000001840 Dandruff Diseases 0.000 title claims abstract description 14
- 230000000638 stimulation Effects 0.000 title claims abstract description 10
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 8
- 240000003870 Ageratum houstonianum Species 0.000 title description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000012676 herbal extract Substances 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 45
- 241000196324 Embryophyta Species 0.000 claims abstract description 42
- 241000544602 Ageratum Species 0.000 claims abstract description 41
- 150000001875 compounds Chemical class 0.000 claims abstract description 41
- 238000009472 formulation Methods 0.000 claims abstract description 41
- 239000002904 solvent Substances 0.000 claims abstract description 33
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 claims abstract description 20
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims abstract description 16
- VMUXSMXIQBNMGZ-UHFFFAOYSA-N 3,4-dihydrocoumarin Chemical compound C1=CC=C2OC(=O)CCC2=C1 VMUXSMXIQBNMGZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000000605 extraction Methods 0.000 claims abstract description 15
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 claims abstract description 13
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 claims abstract description 13
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 claims abstract description 13
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 claims abstract description 12
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 claims abstract description 12
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims abstract description 12
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 12
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940031439 squalene Drugs 0.000 claims abstract description 12
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003085 diluting agent Substances 0.000 claims abstract description 11
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 claims abstract description 10
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940117948 caryophyllene Drugs 0.000 claims abstract description 10
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 claims abstract description 10
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 claims abstract description 10
- OYHQOLUKZRVURQ-UHFFFAOYSA-N 9,12-Octadecadienoic Acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 9
- 238000013459 approach Methods 0.000 claims abstract description 9
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 9
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 8
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 6
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 6
- 229930191710 precocene Natural products 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 25
- CPTJXGLQLVPIGP-UHFFFAOYSA-N precocene I Chemical compound C1=CC(C)(C)OC2=CC(OC)=CC=C21 CPTJXGLQLVPIGP-UHFFFAOYSA-N 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 16
- 239000003921 oil Substances 0.000 claims description 15
- 235000019198 oils Nutrition 0.000 claims description 15
- 238000000638 solvent extraction Methods 0.000 claims description 15
- -1 Caryophyliene Chemical compound 0.000 claims description 14
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 13
- RRUFTPKJXNXMAE-UHFFFAOYSA-N 6-ethenyl-7-methoxy-2,2-dimethylchromene Chemical compound O1C(C)(C)C=CC2=C1C=C(OC)C(C=C)=C2 RRUFTPKJXNXMAE-UHFFFAOYSA-N 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 8
- KZJWDPNRJALLNS-FBZNIEFRSA-N clionasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-FBZNIEFRSA-N 0.000 claims description 8
- QHMGJGNTMQDRQA-UHFFFAOYSA-N dotriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC QHMGJGNTMQDRQA-UHFFFAOYSA-N 0.000 claims description 8
- HMSWAIKSFDFLKN-UHFFFAOYSA-N hexacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC HMSWAIKSFDFLKN-UHFFFAOYSA-N 0.000 claims description 8
- YDLYQMBWCWFRAI-UHFFFAOYSA-N hexatriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC YDLYQMBWCWFRAI-UHFFFAOYSA-N 0.000 claims description 8
- KUPLEGDPSCCPJI-UHFFFAOYSA-N tetracontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC KUPLEGDPSCCPJI-UHFFFAOYSA-N 0.000 claims description 8
- POOSGDOYLQNASK-UHFFFAOYSA-N tetracosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC POOSGDOYLQNASK-UHFFFAOYSA-N 0.000 claims description 8
- GWVDBZWVFGFBCN-UHFFFAOYSA-N tetratriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC GWVDBZWVFGFBCN-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 claims description 6
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 claims description 6
- CMRBCUQYNLDSKE-UHFFFAOYSA-N 3,5,7-trimethoxy-2-(3,4,5-trimethoxyphenyl)chromen-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(C=2OC)=O)C=1OC=2C1=CC(OC)=C(OC)C(OC)=C1 CMRBCUQYNLDSKE-UHFFFAOYSA-N 0.000 claims description 6
- NCTSLPBQVXUAHR-UHFFFAOYSA-N 3,5-ditert-butylbenzoic acid Chemical compound CC(C)(C)C1=CC(C(O)=O)=CC(C(C)(C)C)=C1 NCTSLPBQVXUAHR-UHFFFAOYSA-N 0.000 claims description 6
- LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 claims description 6
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 claims description 6
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 claims description 6
- NIDGCIPAMWNKOA-WOJBJXKFSA-N Neophytadiene Natural products [C@H](CCC[C@@H](CCCC(C)C)C)(CCCC(C=C)=C)C NIDGCIPAMWNKOA-WOJBJXKFSA-N 0.000 claims description 6
- NIDGCIPAMWNKOA-UHFFFAOYSA-N neophytadiene Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(=C)C=C NIDGCIPAMWNKOA-UHFFFAOYSA-N 0.000 claims description 6
- PTIDGSWTMLSGAH-UHFFFAOYSA-N precocene II Chemical compound O1C(C)(C)C=CC2=C1C=C(OC)C(OC)=C2 PTIDGSWTMLSGAH-UHFFFAOYSA-N 0.000 claims description 6
- JXTPJDDICSTXJX-UHFFFAOYSA-N triacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 6
- JNHLHPMTMTYLCP-UHFFFAOYSA-N 1-(4-tert-butyl-2,6-dimethylphenyl)ethanone Chemical compound CC(=O)C1=C(C)C=C(C(C)(C)C)C=C1C JNHLHPMTMTYLCP-UHFFFAOYSA-N 0.000 claims description 5
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- FUCYIEXQVQJBKY-ZFWWWQNUSA-N (+)-δ-Cadinene Chemical compound C1CC(C)=C[C@H]2[C@H](C(C)C)CCC(C)=C21 FUCYIEXQVQJBKY-ZFWWWQNUSA-N 0.000 claims description 4
- GAIBLDCXCZKKJE-QRYCCKSOSA-N (-)-Germacrene D Natural products C(C)(C)[C@H]1/C=C/C(=C)CC/C=C(/C)\CC1 GAIBLDCXCZKKJE-QRYCCKSOSA-N 0.000 claims description 4
- FAMPSKZZVDUYOS-OWEBEESNSA-N (1e,4z,8e)-2,6,6,9-tetramethylcycloundeca-1,4,8-triene Chemical compound C\C1=C/CC(C)(C)\C=C/C\C(C)=C\CC1 FAMPSKZZVDUYOS-OWEBEESNSA-N 0.000 claims description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 4
- JSNRRGGBADWTMC-UHFFFAOYSA-N (6E)-7,11-dimethyl-3-methylene-1,6,10-dodecatriene Chemical compound CC(C)=CCCC(C)=CCCC(=C)C=C JSNRRGGBADWTMC-UHFFFAOYSA-N 0.000 claims description 4
- BZUNJUAMQZRJIP-UHFFFAOYSA-N 15-hydroxypentadecanoic acid Chemical compound OCCCCCCCCCCCCCCC(O)=O BZUNJUAMQZRJIP-UHFFFAOYSA-N 0.000 claims description 4
- IKXCCPWTSIENLL-UHFFFAOYSA-N 2-methyl-5-propan-2-ylbicyclo[3.1.0]hexan-1-ol Chemical compound CC1CCC2(C(C)C)C1(O)C2 IKXCCPWTSIENLL-UHFFFAOYSA-N 0.000 claims description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 4
- GAIBLDCXCZKKJE-YZJXYJLZSA-N Germacren D Chemical compound CC(C)C/1CC\C(C)=C\CCC(=C)\C=C\1 GAIBLDCXCZKKJE-YZJXYJLZSA-N 0.000 claims description 4
- PVAMXWLZJKTXFW-UHFFFAOYSA-N Gitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C1(O)CC(O)C2C1=CC(=O)OC1 PVAMXWLZJKTXFW-UHFFFAOYSA-N 0.000 claims description 4
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 4
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 4
- QMAYBMKBYCGXDH-UHFFFAOYSA-N alpha-amorphene Natural products C1CC(C)=CC2C(C(C)C)CC=C(C)C21 QMAYBMKBYCGXDH-UHFFFAOYSA-N 0.000 claims description 4
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- PHWISBHSBNDZDX-UHFFFAOYSA-N beta-Sesquiphellandrene Natural products CC(C)=CCCC(C)C1CCC(=C)C=C1 PHWISBHSBNDZDX-UHFFFAOYSA-N 0.000 claims description 4
- PHWISBHSBNDZDX-LSDHHAIUSA-N beta-sesquiphellandrene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CCC(=C)C=C1 PHWISBHSBNDZDX-LSDHHAIUSA-N 0.000 claims description 4
- UOKRBSXOBUKDGE-UHFFFAOYSA-N butylphosphonic acid Chemical compound CCCCP(O)(O)=O UOKRBSXOBUKDGE-UHFFFAOYSA-N 0.000 claims description 4
- 229960000956 coumarin Drugs 0.000 claims description 4
- YOCDGWMCBBMMGJ-UHFFFAOYSA-N delta-cadinene Natural products C1C=C(C)CC2C(C(C)C)CCC(=C)C21 YOCDGWMCBBMMGJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- KZJWDPNRJALLNS-STIDJNKJSA-N gamma-sitosterol Natural products CC[C@@H](CC[C@@H](C)[C@@H]1CC[C@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C KZJWDPNRJALLNS-STIDJNKJSA-N 0.000 claims description 4
- OJIGFVZZEVQUNV-UHFFFAOYSA-N germacrene D Natural products CC(C)C1CCC=C(/C)CCC(=C)C=C1 OJIGFVZZEVQUNV-UHFFFAOYSA-N 0.000 claims description 4
- PVAMXWLZJKTXFW-VQMOFDJESA-N gitoxigenin Chemical compound C1([C@H]2[C@@H](O)C[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC4)C)CC[C@@]32C)=CC(=O)OC1 PVAMXWLZJKTXFW-VQMOFDJESA-N 0.000 claims description 4
- QBNFBHXQESNSNP-UHFFFAOYSA-N humulene Natural products CC1=CC=CC(C)(C)CC=C(/C)CCC1 QBNFBHXQESNSNP-UHFFFAOYSA-N 0.000 claims description 4
- GAIBLDCXCZKKJE-UHFFFAOYSA-N isogermacrene D Natural products CC(C)C1CCC(C)=CCCC(=C)C=C1 GAIBLDCXCZKKJE-UHFFFAOYSA-N 0.000 claims description 4
- HOWGUJZVBDQJKV-UHFFFAOYSA-N n-propyl-nonadecane Natural products CCCCCCCCCCCCCCCCCCCCCC HOWGUJZVBDQJKV-UHFFFAOYSA-N 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- USDOQCCMRDNVAH-UHFFFAOYSA-N sigma-cadinene Natural products C1C=C(C)CC2C(C(C)C)CC=C(C)C21 USDOQCCMRDNVAH-UHFFFAOYSA-N 0.000 claims description 4
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims description 4
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 4
- 229940032091 stigmasterol Drugs 0.000 claims description 4
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 4
- 235000016831 stigmasterol Nutrition 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- PFEFOYRSMXVNEL-UHFFFAOYSA-N 2,4,6-tritert-butylphenol Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 PFEFOYRSMXVNEL-UHFFFAOYSA-N 0.000 claims description 3
- PRTCFQOQYWNVJL-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-5-hydroxy-3,6,7,8-tetramethoxychromen-4-one Chemical compound C1=C2OCOC2=CC(C=2OC3=C(C(C=2OC)=O)C(O)=C(C(=C3OC)OC)OC)=C1 PRTCFQOQYWNVJL-UHFFFAOYSA-N 0.000 claims description 3
- WGJPGMJLARWHRK-UHFFFAOYSA-N 3,5-di-tert-Butyl-4-hydroxyacetophenone Chemical compound CC(=O)C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 WGJPGMJLARWHRK-UHFFFAOYSA-N 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- DYLPEFGBWGEFBB-UHFFFAOYSA-N beta-Cedren Natural products C1C23C(C)CCC3C(C)(C)C1C(=C)CC2 DYLPEFGBWGEFBB-UHFFFAOYSA-N 0.000 claims description 3
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 3
- 239000012669 liquid formulation Substances 0.000 claims description 3
- GARQDIVXKVBJFP-UHFFFAOYSA-N p-Octylacetophenone Chemical compound CCCCCCCCC1=CC=C(C(C)=O)C=C1 GARQDIVXKVBJFP-UHFFFAOYSA-N 0.000 claims description 3
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 claims description 3
- DYLPEFGBWGEFBB-GUIRCDHDSA-N β-funebrene Chemical compound C1[C@@]23[C@H](C)CC[C@H]3C(C)(C)[C@H]1C(=C)CC2 DYLPEFGBWGEFBB-GUIRCDHDSA-N 0.000 claims description 3
- SKCKOFZKJLZSFA-KVTDHHQDSA-N (2r,3r,4r,5r)-hexane-1,2,3,4,5-pentol Chemical compound C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SKCKOFZKJLZSFA-KVTDHHQDSA-N 0.000 claims description 2
- FBWMYSQUTZRHAT-HZJYTTRNSA-N (9z,12z)-octadeca-9,12-dienoyl chloride Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(Cl)=O FBWMYSQUTZRHAT-HZJYTTRNSA-N 0.000 claims description 2
- JSNRRGGBADWTMC-QINSGFPZSA-N (E)-beta-Farnesene Natural products CC(C)=CCC\C(C)=C/CCC(=C)C=C JSNRRGGBADWTMC-QINSGFPZSA-N 0.000 claims description 2
- YSNRTFFURISHOU-UHFFFAOYSA-N beta-farnesene Natural products C=CC(C)CCC=C(C)CCC=C(C)C YSNRTFFURISHOU-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims 1
- 239000012674 herbal formulation Substances 0.000 claims 1
- MIDSQDHRRBSMIZ-UHFFFAOYSA-N hexadec-2-en-1-ol Chemical compound CCCCCCCCCCCCCC=CCO MIDSQDHRRBSMIZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 238000011176 pooling Methods 0.000 claims 1
- 239000002453 shampoo Substances 0.000 abstract description 7
- 230000000699 topical effect Effects 0.000 abstract description 5
- 230000001476 alcoholic effect Effects 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 17
- 244000296912 Ageratum conyzoides Species 0.000 description 10
- 201000004384 Alopecia Diseases 0.000 description 8
- 230000003676 hair loss Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 210000003780 hair follicle Anatomy 0.000 description 6
- 208000024963 hair loss Diseases 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 230000003797 telogen phase Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010016936 Folliculitis Diseases 0.000 description 4
- 241000555688 Malassezia furfur Species 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000003778 catagen phase Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 230000003803 hair density Effects 0.000 description 2
- 229940124563 hair growth stimulant Drugs 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000003170 nutritional factors Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229940095673 shampoo product Drugs 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000002271 trichotillomania Diseases 0.000 description 2
- 238000007738 vacuum evaporation Methods 0.000 description 2
- ZNZLXMVSALEVHW-UHFFFAOYSA-N 5-hydroxypentadecanoic acid Chemical compound CCCCCCCCCCC(O)CCCC(O)=O ZNZLXMVSALEVHW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 240000003173 Drymaria cordata Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000000391 Lepidium draba Nutrition 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000036621 balding Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000008371 chromenes Chemical class 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000012505 colouration Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000003661 hair follicle regeneration Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
- A61K8/70—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Definitions
- Embodiments are generally related to the field of pharmaceutics, cosmetics and allied industries. Embodiments are also related to herbal extracts for stimulation of hair growth, control of hair fall, dandruff and infections thereof. Embodiments are particularly related to an herbal extraction process for preparing hair growth simulator using herbaceous plants, Ageratum spp. (Ageratum conyzoides (Synonym: Ageratum cperuleum) and Ageratum houstonianum)
- Hair loss/hair fall has become a ubiquitous affliction of human beings (both male and female gender) with the growing impact of global pollution and lifestyle changes.
- Most common reasons of radical or premature hair loss/hair fall are genetic predisposition, endocrine disorders, medication, radiation, chemotherapy, and exposure to chemicals, nutritional factors, generalized or local skin diseases, stress, child birth, Alopecia areata and mechanical damage such as Trichotillomania, hair styling treatment, hair braids and weaves.
- the hair in humans is generated by the hair follicles implanted in the scalp.
- a healthy head of hair is said to contain between 100000 and 150000 hairs, and each hair within this head of hair possesses its own cycle.
- the life cycle of the hair can be. described in three successive physiological phases such as, Anagen, Catagen and Telogen.
- Anagen is a phase of hair growth which may last from a few weeks to 10 years
- Catagen phase is a transient phase of involution of the follicle and ceasing of hair growth with degeneration of the root which may last for a few weeks
- Telogen is a phase of shedding of the hair with the root moving up towards the surface by lasting 1 to 5 months.
- Telogen phase the hair therefore disappears from the scalp and this disappearance may extend from a few days to a few months before the follicle is reactivated to give a new hair in the Anagen phase.
- plugs of skin containing hair are transplanted from areas of the scalp where hair was growing to bald or balding areas of the scalp.
- the transplantation technique can be a time-consuming and relatively costly affair.
- Other approaches include ultra-violet radiation and exercise therapy. While cosmetic aids are another significant approach for the stimulation of hair-growth, there is still a need in the art for compounds which may have greater stimulatory effect on hair growth.
- An herbal preparation for stimulation of hair growth and control of hair fall, dandruff and infections thereof using herbaceous plants, Ageratum spp. (including Ageratum conyzoides, Ageratum coeru!eum and Ageratum houstonianum) is disclosed herein. At least one compound of plants, Ageratum spp.
- CPEA Common Plant Extraction Approach
- the extraction of compounds can be performed utilizing an ethanol solvent and a methanol solvent (i.e., alcoholic solvents) separately and the concentrated materials obtained at both the solvents are pooled together (or separately) in order to obtain an herbal extract for simulating the follicles of the hair.
- the compounds of plants, Ageratum spp. in combination with an acceptable carrier or diluent can be further prepared into an herbal extract formulations such as, a liquid, oil or gel formulation for topical application.
- Such an herbal preparation using plants, Ageratum spp. can be utilized as an efficient hair care solution in a wide range of hair growth related problems of humans in a cost effective manner.
- the Common Plant Extraction Approach (CPEA) described herein can be a principle extraction technique that is well known in the art for extracting the compounds of a plant. Initially, the leaves and soft stems of Ageratum spp. (preferably 60 to 90 days old plants) can be sliced into pieces (approx. 1 cm size) and shade dried at room temperature. The sliced pieces can be also dried using a fluid flash dryer. Further, a mechanized pulverizing machine can be employed to grind the dried plant slices into coarse powder in order to thereby extract the compounds using the ethanol and methanol solvents separately.
- the solvent extraction process described herein can be performed at a 1 :10 (W/V) ratio using a soxhlet apparatus in order to thereby separate the green colored solvent extracts using a rotoevaporator.
- the compounds obtained at both the ethanol solvent extraction process and the methanol solvent extraction process are further pooled together (or used separately) in order to form the herbal extract for simulating the hair growth.
- the compounds extracted at the methanol solvent extraction process can be such as, for example, but not limited to, N ) N-bis(trimethylsilyl)-2-phenyl-7-(trifluoromethyl)quinolon-4-amine, 1 - deoxy-d-mannitol, 15-hydroxypentadecanoic acid, 2-chromenone, 3',4 ⁇ 5, 6,7,8- hexamethoxyflavone, 3,5-di-tert-butylbenzoic acid, 3,7, 1 ,15-tetramethylhexadec-2-eh- 1-ol, 4-tert-butyl-2,6-dimethylacetophenone, 6-vinyl-7-methoxy-2,2-dimethylchromene, Anhydro-d-mannosan, Beta-Funebre
- the compounds extracted at the ethanol solvent extraction process can be such as, for example, but not limited to, N,N-bis(trimethylsilyl)-2-phenyl-7- (trifluoromethyl)quinolon-4-amine, (Z)-,Beta-farnesene, 1-(3,5-ditert-butyl-4- hydroxyphenyl)ethanone, 2-(1 ,3-benzodioxol-5-yl)-5-hydroxy-3,6,7,8-tetramethoxy-4h- chromen-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1 -benzopyran-4-one, 2,4,6-tri-tert-butylphenol, 2-chromanone, 2H-chromen-2-one, 3', 4', 5,6,7, 8- hexamethoxyflavone, 3,5-di-tert-butylbenzoic acid, 3,7, 11
- the solvents utilized for extracting compounds herein should not be construed in any limited sense. Those skilled in the art can understand that similar kind of solvents such as hexane, ethyl acetate, acetone, chloroform, dichloromethane, etc. can also tried for preparing herbal extraction and developing the hair growth stimulant formulation.
- the herbal extract is further formulated with an acceptable carrier or diluent in order to formulate as liquid, shampoo, oil or gel for topical application.
- the .'nerbai extract can be dissolved in the sterile Distilled water (at 1 -5 g/l) and the aqueous suspension can be filtered (through 1 to 5 ⁇ filter, pH adjusted to neutral) in order to form a liquid formulation of the herbal extract.
- the herbal extract is dissolved in vegetable oil or PG/PL and the suspension is filtered (through 1 to 5 ⁇ filter) in order to form an oil formulatidn.
- the herbal extract can be dissolved in a small quantity of ethanol and filtered (through 1 to 5 ⁇ filter) in order to form the gel formulation.
- the mixture can be mixed vigorously using mechanized homogenizer to get the uniform gel product.
- FIG. 1 illustrates a perspective view of a process for preparing an herbal extract formulation using herbaceous plants, Ageratum spp., in accordance with the disclosed embodiments.
- FIG. 2 illustrates a high level flow chart of operations illustrating logical operational steps of a method for preparing herbal extract formulation using herbaceous plants, Ageratum spp., in accordance with the disclosed embodiments.
- FIG. 1 illustrates a perspective view of a process 100 for preparing an herbal extract formulation 190 using herbaceous plants, Ageratum spp. (including Ageratum conyzoides, Synonym: Ageratum coeruleum) and Ageratum houstonianum) .1 10, in accordance with the disclosed embodiments.
- Ageratum spp. are annual herbaceous plants belonging to the family Asteraceae. They are common weeds and grow rapidly. They are known by several names such as goat weed, chick weed, white weed, etc.
- Ageratum spp. are found in many countries ranging from Southeastern North America to Central America, Asia and Africa; but the center of origin is in Central America and the Caribbean. Ageratum spp. are also found in several countries in tropical and subtropical regions, including India, Brazil, Vietnam, Nigeria, Kenya, Congo, Cameroon, etc. in abundance.
- Ageratum spp. are very valuable herbs as they contain many bioactive compounds including flavonoids, alkaloids, cumarins, essential oils, chromenes, benzofurans, terpenoids and tannins that have medicinal, antimicrobial and insecticidal properties.
- the extracts of Ageratum conyzoides 1 10 and other Ageratum species have been used to cure a wide range of ailments such as muscle pains, inflammations, dysentery, indigestion, constipation, wounds in humans.
- the use of Ageratum spp. 1 10 in stimulation of hair follicles is novel. It has not hitherto been known that Ageratum spp. 10 have a simulative action on hair growth and hair fall control.
- a Common Plant Extraction Approach is adapted to prepare the herbal extract from Aageratum spp. 10.
- the Common Plant Extraction Approach (CPEA) described herein can be a principle extraction technique that is well known in the art for extracting the compounds 180 of plants. Note that other extraction processes can be alternatively employed in the place of suggested without losing the scope of invention.
- the leaves and soft stems of Ageratum spp. 0 preferably 60 to 90 days old plants are initially sliced into pieces 120 (i.e., approx. 1 cm) and shade dried at room temperature (approx. 28-30°C) for 48 hrs to 72 hrs.
- The. sliced pieces 120 can be also dried at 45°C using a fluid flash dryer for 24 hrs.
- the dried plant slices 120 are ground to course powder using a mechanized pulverizing machine 130 in order to thereby extract the compounds 180 using the ethanol solvent 160, methanol solvent 170 and other solvents separately.
- the solvent extraction process described herein can be " performed at a 1 :10 (W/V) ratio using a soxhlet apparatus in order thereby separate the green colored solvent extracts using a rotoevaporator.
- the solvents utilized for extracting compounds herein should not be construed in any limited sense. Those skilled in the art can understand that similar kind of solvents such as hexane, ethy! acetate, acetone, chloroform, dichloromethane, etc. can also tried for preparing herbal extraction and developing the hair growth stimulant formulation.
- the compounds extracted at the methanol solvent extraction process 150 can be such as, for example, but not limited to, N,N-bis(trimethylsilyl)-2-phenyl-7- (trifluoromethyl)quinolon-4-amine, -deoxy-d-mannitol, 5-hydroxypentadecanoic acid, 2-chromenone, 3',4',5,6,7,8-hexamethoxyflavone, 3,5-di-tert-butylbenzoic acid, 3,7,1 1 ,15-tetramethylhexadec-2-en-1-ol, 4-tert-butyl-2,6-dimethylacetophenone, 6-vinyl- 7-methoxy-2,2-dimethylchrpmene, Anhydro-d-mannosan, Beta-Funebrene, Caryophyllene, Coumarin, Hexa-o-methylmyricitin, Hydrocoumarin, LinoleoyI chloride, Methyl c
- Table 1 illustrates the list of compounds extracted by treating the plant material 120 using the methanol solvent 170.
- the compounds extracted at the ethanol solvent extraction process can be such as, for example, but not limited to, N,N-bis(trimethylsilyl)-2-phenyl- 7-(trifluoromethyl)quinolon-4-amine, (Z)-,Beta-famesene, 1 -(3,5-ditert-butyl-4- hydroxyphenyl)ethanone, 2-(1 ,3-benzodioxol-5-yl)-5-hydroxy-3,6,7,8-tetramethoxy-4h- chromen-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy ⁇ 4H-1-benzopyran-4- one, 2,4,6-tri-tert-butylphenol, 2-chromanone, 2H-chromen-2-one, 3', 4', 5,6, 7,8- hexamethoxyflavone, 3,5-di-tert-butylbenzoic acid
- Table 2 illustrates the list of compounds extracted by treating the plant material 120 using the ethanol solvent 170.
- the green colored solvent extract from ethanol/methanol/other solvents are removed using vacuum evaporation.
- Ageratum spp. four compounds, 9,12-octadecadienoic acid (Z,Z)-, Alpha-linolenic acid, Hexadeconoic acid and Hydrocoumarin are identified as 5 Alpha-reductase inhibitors.
- the 5 alpha reductase enzyme metabolizes the testosterone (male hormone) into dihydrotestosterone (DHT), which is known to induce scalp hair loss in man.
- DHT dihydrotestosterone
- the 5 alpha reductase inhibitors present in the extracts of Ageratum spp. can attach with 5 alpha reductase enzyme and prevent it to convert the testosterone into DHT. Thereby decrease and stop the hair loss.
- Table 3 illustrates the list of four compounds identified as 5 Alpha reductase inhibitors present in both ethanol and methanol extracts of the hair growth product.
- Table 3 [0029] The compounds obtained at both the ethanol solvent extraction process 140 and the methanol solvent extraction process 150 (and other solvent processes) are further pooled together in order to form the herbal extract 180 for simulating the hair growth.
- the green colored solvent extracts are separated and the ethanol/methanol/other solvents are removed using vacuum evaporation.
- Table 4 illustrates the list of six major compounds identified as common components present in both ethanol and methanol extracts of the hair growth product.
- the herbal extract contains the above 5 alpha reductase inhibitors and other major compounds of plants, Aageratum spp. 1 10 in combination with an acceptable carrier or diluent can be further prepared into an herbal extract formulations 190 such as, aqueous (liquid), gel, oil or shampoo formulation for topical application.
- the herbal extract of Ageratum spp. with the above mentioned compounds can be dissolved in the sterile distilled water (at 1-5 g/l) and the aqueous suspension can be filtered (through 1 to 5 ⁇ filter, pH adjusted to neutral) in order to form a liquid formulation 192 of the herbal extract.
- the herbal extract is dissolved in vegetable oil/PG/PL and the suspension is filtered (through 1 to 5 ⁇ filter) in order to form an oil formulation 194.
- the herbal extract can be dissolved in a small quantity of ethanol and filtered (through 1 to 5 ⁇ filter) in order to form the gel formulation 96.
- the mixture can be mixed vigorously using mechanized homogenizer to get the uniform gel product.
- the herbal extract can be dissolved in an acceptable carrier or diluent in order to get the shampoo formulation 198.
- the mixture can be mixed vigorously using mechanized homogenizer to get the uniform shampoo product.
- the herbal extract formulation 190 disclosed herein can be utilized to effectively control the hair loss due to scenarios such as, but not limited to, genetic predisposition, endocrine disorders, medication, radiation, chemotherapy, exposure to chemicals, nutritional factors, generalized or local skin diseases, stress, child birth, Alopecia areata and mechanical damage, Trichotillomania, hair styling treatment, hair braids and weaves.
- the herbal extract formulation 190 prevents the cease of production of hair due to physiological phase changes such as, Anagen, Catagen and Telogen in humans.
- FIG. 2 illustrates a high level flow chart of operations illustrating logical operational steps of a method 200 for preparing an herbal extract formulation 190 using herbaceous plants, Ageraium spp. 110, in accordance with the disclosed embodiments.
- identical or similar blocks are generally indicated by identical reference numerals.
- the plants, Ageratum spp. 1 10 with 60 to 90 days of age can be identified and the leaves and soft stems of the Ageratum spp. 1 10 can be sliced into pieces (approx. 1 cm size) 120, as illustrated at block 205.
- 1 10 can be further shade dried at room temperature or dried at 45°C using a fluid flash dryer, as depicted at block 210.
- a mechanized pulverizing machine 130 can be employed to grind the dried plant slices 20 into coarse powder, as illustrated at block 215.
- the plant material can be further extracted using the ethanol and methanol solvents and other solvents 160 and 170 separately, as depicted at blocks 220 and 230.
- the solvent extraction process 140 and 150 described herein can be performed at a 1 :10 (WA/) ratio using a soxhlet apparatus.
- the green colored solvents can be further extracted and separated by removing ethanol/methanol/other solvents 160 and 170 using a rotoevaporator, as illustrated at blocks 225 and 235.
- the compounds obtained at both the ethanol solvent extraction process 140 and the methanol solvent extraction process 1 50 can be pooled together or separately in order to form the herbal extract 180 for simulating the hair growth, as depicted at block 240.
- six major compounds including N,N-bis(trimethylsilyl)-2- phenyl-7-(trifluoromethyl)quinolon-4-amine, S' ⁇ '.S /.S-hexamethoxyflavone, Phytol, Precocene, Caryophyllene, Squalene are identified as common marker components in the hair growth product.
- the concentrated herbal extract 180 can be further formulated with an acceptable carrier or diluent in order to formulate as liquid, oil, gel or shampoo for topical application.
- the purified form of herbal extract 180 can be dissolved in the sterile distilled water (at 1-5 g/l) in order to filter the aqueous suspension (through 1 to 5 ⁇ filter, pH adjusted to neutral), as illustrated at block 250.
- the concentrated material can be further added with acceptable carrier or diluent in order to form the aqueous (liquid) formulation 192 of the herbal extract, as illustrated at block 255.
- the herbal extract 180 can be dissolved in vegetable oil/PG/PL in order to filter the suspension (through 1 to 5 ⁇ filter), as illustrated at block 260.
- the concentrated extract 180 can be further added with the acceptable carrier and diluent (e.g., coconut oil) in order to form the oil formulation 94, as depicted at block 265.
- the concentrated materia! 180 can be dissolved in a small quantity of ethanol in order to filter the suspension (through 1 to 5 ⁇ filter), as illustrated at block 270.
- the concentrated materia! 180 can be further added with the acceptable carrier and diluent in order to form the gel formulation 196, as depicted at block 275.
- the mixture can be mixed vigorously using mechanized homogenizer to get the uniform gel product 196.
- the concentrated material 180 can be further added with the acceptable carrier and diluent in order to form the shampoo formulation 198, as depicted at block 275.
- the mixture can be mixed vigorously using mechanized homogenizer to get the uniform shampoo product 198.
- the aqueous (liquid), oil, gel and shampoo formulations 192, 194, 196 and 198 of the herbal extracts are packed separately in PP bottles aseptically.
- Such an herbal preparation using plants, Ageratum spp. can be utilized as an efficient hair care solution in a wide range of hair growth related problems of humans in a cost effective manner.
- Group-ll Placebo - 1 (Gel excluding herbal extract)
- Group-Ill Placebo - 2 (Aqueous excluding herbal extract)
- Group-IV Placebo - 3 (Oil excluding herbal extract)
- Group-VI Formulation - 2 (Aqueous with herbal extract)
- Group I acted as a negative control and Group VIII acted as a positive control.
- the positive control group received (standard market product) as test compound according to the standard procedures. All the three formulations alone excluding the active principle were kept as Placebo (Group II, HI, and IV). Hair depilation was made by paraffin wax strips. All the test formulations were applied at 24 hours intervals and the animals were kept under observations on changes in skin colour. Since the chosen mice displayed change in the skin colour with reference to hair growth, the indication on skin colour implies the efficacy of the test formulations. It has been observed that both negative control and placebo groups displayed normal hair growth profile, whereas mice in the groups of V, VI, VII and VIII have displayed advancement in hair giowth pattern.
- the hair density was maximum in Group VIII, followed by V!! and V and the size of hair and hair bulb nature were also significant changed in the above Groups mice compared to negative control and Placebo treated mice.
- the gel and oil formulations were more effective than the aqueous formulation.
- the aqueous formulation induced localized hair growth profile, because of non-adherence to the skin, the expected results were not obtained.
- the agar plates were prepared and the dandruff pathogens, Pityrosporum ovale and Pityrosporum folliculitis were inoculated over the agar surface.
- Four wells were made using sterile cork borer and 10% aqueous herbal extract of A. conyzoides was ' added at 50 and 100 pi in respective well.
- Commercial fungicide, Ketaconazole at 100 pg/ml (Positive control) and sterile water (Negative control) were also added in respective wells.
- the plates were incubated at room temperature for seven days and observed for the inhibition of fungal growth.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
An herbal preparation for stimulation of hair growth and control of hair fall, dandruff and infections thereof using herbaceous plants, Ageratum spp. At least one compound of plants, Ageratum spp. such as, for example, N,N-bis(trimethylsilyl)-2-phenyl-7-(trifluoromethyl)quinolon-4-amine, 3',4',5,6,7,8-hexamethoxyflavone, Phytol, Precocene, Caryophyllene, Squalene, α-linolenic acid, 9,12-octadecadienoic acid (Z,Z)-, Hexadeconoic acid and Hydrocoumarin can be extracted utilizing a Common Plant Extraction Approach. The extraction of the compounds can be performed utilizing an ethanol solvent and a methanol solvent (i.e., alcoholic solvents) separately and the concentrated materials obtained at both the solvents are pooled together or used independently in order to obtain an herbal extract for simulating the follicles of the hair. The compounds of plants Ageratum spp. in combination with an acceptable carrier or diluent can be further prepared into an herbal extract formulations such as, aqueous (including shampoo), oil or gel for topical application. Such an herbal preparation using plants, Ageratum spp. can be utilized as an efficient hair care solution in a wide range of hair growth related problems of humans in a cost effective manner.
Description
HERBAL PREPARATION FOR STIMULATION OF HAIR GROWTH, CONTROL OF HAIR FALL, DANDRUFF AND INFECTIONS THEREOF USING AGERATUM SPP.
TECHNICAL FIELD
[0001] Embodiments are generally related to the field of pharmaceutics, cosmetics and allied industries. Embodiments are also related to herbal extracts for stimulation of hair growth, control of hair fall, dandruff and infections thereof. Embodiments are particularly related to an herbal extraction process for preparing hair growth simulator using herbaceous plants, Ageratum spp. (Ageratum conyzoides (Synonym: Ageratum cperuleum) and Ageratum houstonianum)
BACKGROUND OF THE INVENTION
[0002] Hair loss/hair fall has become a ubiquitous affliction of human beings (both male and female gender) with the growing impact of global pollution and lifestyle changes. Most common reasons of radical or premature hair loss/hair fall are genetic predisposition, endocrine disorders, medication, radiation, chemotherapy, and exposure to chemicals, nutritional factors, generalized or local skin diseases, stress, child birth, Alopecia areata and mechanical damage such as Trichotillomania, hair styling treatment, hair braids and weaves.
[0003] In general, the hair in humans is generated by the hair follicles implanted in the scalp. A healthy head of hair is said to contain between 100000 and 150000 hairs, and each hair within this head of hair possesses its own cycle. The life cycle of the hair can be. described in three successive physiological phases such as, Anagen, Catagen and Telogen. Anagen is a phase of hair growth which may last from a few weeks to 10 years, Catagen phase is a transient phase of involution of the follicle and ceasing of hair growth with degeneration of the root which may last for a few weeks and Telogen is a phase of shedding of the hair with the root moving up towards the surface by lasting 1 to 5 months. At the end of Telogen phase, the hair therefore disappears from the scalp and this disappearance may extend from a few days to a few months before the follicle
is reactivated to give a new hair in the Anagen phase.
[0004] Unfortunately, after a certain number of cycles, the follicle permanently ceases its production and the hair may be regarded as dead which may lead to baldness. As baldness progresses, there is a shift in the percentages of hair follicles in each phase with the majority shifting from Anagen to Telogen. The size of hair follicles is also known to decrease while the total number remains relatively constant. A variety of devices and procedures are adapted to simulate the hair follicles and re-generate the hair growth in such cases. Most of the prior art approaches either employ a simulator device or a drug for the hair growth. One such common technique is hair transplantation. Briefly, plugs of skin containing hair are transplanted from areas of the scalp where hair was growing to bald or balding areas of the scalp. The transplantation technique can be a time-consuming and relatively costly affair. Other approaches include ultra-violet radiation and exercise therapy. While cosmetic aids are another significant approach for the stimulation of hair-growth, there is still a need in the art for compounds which may have greater stimulatory effect on hair growth.
[0005] Based on the foregoing a need therefore exists for an improved herbal preparation for stimulation of hair growth, control of hair fall, dandruff and infections thereof using plants, Ageratum spp., as described in greater detail herein.
BRIEF SUMMARY
[0006] The following summary is provided to facilitate an understanding of some of the innovative features unique to the disclosed embodiment and is not intended to be a full description. A full appreciation of the various aspects of the embodiments disclosed herein can be gained by taking the entire specification, claims, drawings, and abstract as a whole.
[0007] It is, therefore, one aspect of the disclosed embodiments to provide an improved herbal extraction for stimulating hair growth.
[0008] It is another aspect of the disclosed embodiments to provide an improved method for extracting compounds of plants, Ageratum spp.
[0009] It is further aspect of the disclosed embodiments to provide an improved herbal preparation for stimulation of hair growth, control of hair fall, dandruff and infections thereof using plants, Ageratum spp.
[0010] The aforementioned aspects and other objectives and advantages can now be achieved as described herein. An herbal preparation for stimulation of hair growth and control of hair fall, dandruff and infections thereof using herbaceous plants, Ageratum spp. (including Ageratum conyzoides, Ageratum coeru!eum and Ageratum houstonianum) is disclosed herein. At least one compound of plants, Ageratum spp. such as, N,N-bis(trimethyls)lyl)-2-phenyl-7-(trifluoromethyl)quinolon-4-amine, 3',4',5,6,7,8-hexamethoxyflavone, Phytol, Precocene, Caryophyllene, Squalene, a- linolenic acid, 9,12-octadecadienoic acid (Z,Z)-, Hexadeconoic acid and Hydrocoumarin can be extracted utilizing a Common Plant Extraction Approach (CPEA). The extraction of compounds can be performed utilizing an ethanol solvent and a methanol solvent (i.e., alcoholic solvents) separately and the concentrated materials obtained at both the solvents are pooled together (or separately) in order to obtain an herbal extract for simulating the follicles of the hair. The compounds of plants, Ageratum spp. in
combination with an acceptable carrier or diluent can be further prepared into an herbal extract formulations such as, a liquid, oil or gel formulation for topical application. Such an herbal preparation using plants, Ageratum spp. can be utilized as an efficient hair care solution in a wide range of hair growth related problems of humans in a cost effective manner.
[0011] The Common Plant Extraction Approach (CPEA) described herein can be a principle extraction technique that is well known in the art for extracting the compounds of a plant. Initially, the leaves and soft stems of Ageratum spp. (preferably 60 to 90 days old plants) can be sliced into pieces (approx. 1 cm size) and shade dried at room temperature. The sliced pieces can be also dried using a fluid flash dryer. Further, a mechanized pulverizing machine can be employed to grind the dried plant slices into coarse powder in order to thereby extract the compounds using the ethanol and methanol solvents separately. The solvent extraction process described herein can be performed at a 1 :10 (W/V) ratio using a soxhlet apparatus in order to thereby separate the green colored solvent extracts using a rotoevaporator.
[0012] The compounds obtained at both the ethanol solvent extraction process and the methanol solvent extraction process are further pooled together (or used separately) in order to form the herbal extract for simulating the hair growth. The compounds extracted at the methanol solvent extraction process can be such as, for example, but not limited to, N)N-bis(trimethylsilyl)-2-phenyl-7-(trifluoromethyl)quinolon-4-amine, 1 - deoxy-d-mannitol, 15-hydroxypentadecanoic acid, 2-chromenone, 3',4\5, 6,7,8- hexamethoxyflavone, 3,5-di-tert-butylbenzoic acid, 3,7, 1 ,15-tetramethylhexadec-2-eh- 1-ol, 4-tert-butyl-2,6-dimethylacetophenone, 6-vinyl-7-methoxy-2,2-dimethylchromene, Anhydro-d-mannosan, Beta-Funebrene, Caryophyllene, Coumarin, Hexa-o- methylmyricitin, Hydrocoumarin, Linoleoyl chloride, Methyl cis-1 1 ,14,17-icosatrienoate, Methyl linoleate, Neophytadiene, p-Octylacetophenone, Phenol, 2,4,6-tris(1 ,1- dimethylethyl), Phytol, Precocene I and Squalene.
[0013] The compounds extracted at the ethanol solvent extraction process can be
such as, for example, but not limited to, N,N-bis(trimethylsilyl)-2-phenyl-7- (trifluoromethyl)quinolon-4-amine, (Z)-,Beta-farnesene, 1-(3,5-ditert-butyl-4- hydroxyphenyl)ethanone, 2-(1 ,3-benzodioxol-5-yl)-5-hydroxy-3,6,7,8-tetramethoxy-4h- chromen-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1 -benzopyran-4-one, 2,4,6-tri-tert-butylphenol, 2-chromanone, 2H-chromen-2-one, 3', 4', 5,6,7, 8- hexamethoxyflavone, 3,5-di-tert-butylbenzoic acid, 3,7, 11 ,15-tetramethylhexadec-2-en- 1-ol, 3-thujanol, 4-tert-butyl-2,6-dimethy!acetophenone, 6-demethoxyageratochromene, 6-vinyl-7-methoxy-2,2-dimethylchromene, 9,12-octadecadienoic acid (Z,2)-, All-trans- squalene, Alpha-benzopyrone, Alpha-caryophyllene, Alpha-linolenic acid, Alpha- tocopherol- -D-mannoside, Beta-sesquiphellandrene, Butylphosphonic acid, hexyl 4-(2- phenylprop-2-yl)phenyl ester, Caryophyllene, Coumariri, Delta-cadinene, Dotriacontane, Gamma-mourolen, Gamma-sitosterol, Germacrene D, Gitoxigenin, Hexacosane, Hexadeconoic acid, Hydrocoumarin, Methyl cis-1 ,14, 17-icosatrienoate, Methyl linoleate, Methyl palrnitate, Neophytadiene, N-hexatriacontane, n-tertacontane, N- tetracosane, N-tetratriacontane, N-thacontane, Phytol, Precocene I, Precocene il, Squalene, Stigmasterol, Stimasta-4,2,2-dien-3, -ol, and Tetracontane.
[0014] The solvents utilized for extracting compounds herein should not be construed in any limited sense. Those skilled in the art can understand that similar kind of solvents such as hexane, ethyl acetate, acetone, chloroform, dichloromethane, etc. can also tried for preparing herbal extraction and developing the hair growth stimulant formulation. The herbal extract is further formulated with an acceptable carrier or diluent in order to formulate as liquid, shampoo, oil or gel for topical application. The .'nerbai extract can be dissolved in the sterile Distilled water (at 1 -5 g/l) and the aqueous suspension can be filtered (through 1 to 5 μ filter, pH adjusted to neutral) in order to form a liquid formulation of the herbal extract. Similarly, the herbal extract is dissolved in vegetable oil or PG/PL and the suspension is filtered (through 1 to 5 μ filter) in order to form an oil formulatidn. The herbal extract can be dissolved in a small quantity of ethanol and filtered (through 1 to 5 μ filter) in order to form the gel formulation. The mixture can be mixed vigorously using mechanized homogenizer to get the uniform gel product.
BRIEF DESCRIPTION OF THE DRAWINGS
[0015] The accompanying figures, in which like reference numerals refer to identical or functionally-similar elements throughout the separate views and which are incorporated in and form a part of the specification, further illustrate the present invention and, together with the detailed description of the invention, serve to explain the principles of the present invention.
[0016] FIG. 1 illustrates a perspective view of a process for preparing an herbal extract formulation using herbaceous plants, Ageratum spp., in accordance with the disclosed embodiments; and
[0017] FIG. 2 illustrates a high level flow chart of operations illustrating logical operational steps of a method for preparing herbal extract formulation using herbaceous plants, Ageratum spp., in accordance with the disclosed embodiments.
DETAILED DESCRIPTION
[0018] The particular values and configurations discussed in these non-limiting examples can be varied and are cited merely to illustrate at least one embodiment and are not intended to limit the scope thereof.
[0019] The embodiments now will be described more fully hereinafter with reference to the accompanying drawings, in which illustrative embodiments of the invention are shown. The embodiments disclosed herein can be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. Like numbers refer to like elements throughout. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.
[0020] FIG. 1 illustrates a perspective view of a process 100 for preparing an herbal extract formulation 190 using herbaceous plants, Ageratum spp. (including Ageratum conyzoides, Synonym: Ageratum coeruleum) and Ageratum houstonianum) .1 10, in accordance with the disclosed embodiments. Ageratum spp. are annual herbaceous plants belonging to the family Asteraceae. They are common weeds and grow rapidly. They are known by several names such as goat weed, chick weed, white weed, etc. Ageratum spp. are found in many countries ranging from Southeastern North America to Central America, Asia and Africa; but the center of origin is in Central America and the Caribbean. Ageratum spp. are also found in several countries in tropical and subtropical regions, including India, Brazil, Vietnam, Nigeria, Kenya, Congo, Cameroon, etc. in abundance.
[0021] Ageratum spp. are very valuable herbs as they contain many bioactive compounds including flavonoids, alkaloids, cumarins, essential oils, chromenes,
benzofurans, terpenoids and tannins that have medicinal, antimicrobial and insecticidal properties. The extracts of Ageratum conyzoides 1 10 and other Ageratum species have been used to cure a wide range of ailments such as muscle pains, inflammations, dysentery, indigestion, constipation, wounds in humans. The use of Ageratum spp. 1 10 in stimulation of hair follicles is novel. It has not hitherto been known that Ageratum spp. 10 have a simulative action on hair growth and hair fall control.
[0022] A Common Plant Extraction Approach (CPEA) is adapted to prepare the herbal extract from Aageratum spp. 10. The Common Plant Extraction Approach (CPEA) described herein can be a principle extraction technique that is well known in the art for extracting the compounds 180 of plants. Note that other extraction processes can be alternatively employed in the place of suggested without losing the scope of invention. The leaves and soft stems of Ageratum spp. 0 preferably 60 to 90 days old plants are initially sliced into pieces 120 (i.e., approx. 1 cm) and shade dried at room temperature (approx. 28-30°C) for 48 hrs to 72 hrs. The. sliced pieces 120 can be also dried at 45°C using a fluid flash dryer for 24 hrs. Further, the dried plant slices 120 are ground to course powder using a mechanized pulverizing machine 130 in order to thereby extract the compounds 180 using the ethanol solvent 160, methanol solvent 170 and other solvents separately. The solvent extraction process described herein can be" performed at a 1 :10 (W/V) ratio using a soxhlet apparatus in order thereby separate the green colored solvent extracts using a rotoevaporator. Note that the solvents utilized for extracting compounds herein should not be construed in any limited sense. Those skilled in the art can understand that similar kind of solvents such as hexane, ethy! acetate, acetone, chloroform, dichloromethane, etc. can also tried for preparing herbal extraction and developing the hair growth stimulant formulation.
[0023] The compounds extracted at the methanol solvent extraction process 150 can be such as, for example, but not limited to, N,N-bis(trimethylsilyl)-2-phenyl-7- (trifluoromethyl)quinolon-4-amine, -deoxy-d-mannitol, 5-hydroxypentadecanoic acid, 2-chromenone, 3',4',5,6,7,8-hexamethoxyflavone, 3,5-di-tert-butylbenzoic acid, 3,7,1 1 ,15-tetramethylhexadec-2-en-1-ol, 4-tert-butyl-2,6-dimethylacetophenone, 6-vinyl-
7-methoxy-2,2-dimethylchrpmene, Anhydro-d-mannosan, Beta-Funebrene, Caryophyllene, Coumarin, Hexa-o-methylmyricitin, Hydrocoumarin, LinoleoyI chloride, Methyl cis-11 ,14, 7-icosatrienoate, Methyl linoleate, Neophytadiene, p- Octylacetophenone, Phenol, 2,4,6-tris(1 ,1-dimethylethyl), Phytol, Precocene I and Squalene.
[0024] Table 1 illustrates the list of compounds extracted by treating the plant material 120 using the methanol solvent 170.
[0025] Similarly, the compounds extracted at the ethanol solvent extraction process can be such as, for example, but not limited to, N,N-bis(trimethylsilyl)-2-phenyl- 7-(trifluoromethyl)quinolon-4-amine, (Z)-,Beta-famesene, 1 -(3,5-ditert-butyl-4- hydroxyphenyl)ethanone, 2-(1 ,3-benzodioxol-5-yl)-5-hydroxy-3,6,7,8-tetramethoxy-4h- chromen-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy~4H-1-benzopyran-4- one, 2,4,6-tri-tert-butylphenol, 2-chromanone, 2H-chromen-2-one, 3', 4', 5,6, 7,8- hexamethoxyflavone, 3,5-di-tert-butylbenzoic acid, 3,7,11 ,15-tetramethylhexadec-2-en- ■1-ol, 3-thujanol, 4-tert-butyl-2,6-dimethylacetophenone, 6-demethoxyageratochromene, 6-vinyl-7-methoxy-2,2-dimethylchromene, 9,12-octadecadienoic acid (Z,Z)-, All-trans- squalene, Alpha-benzopyrone, Alpha-caryophyllene, Alpha-linolenic acid, Alpha- octadecanoic acid, Alpha-tocopherol-P-D-mannoside, Beta-sesquiphellandrene, Butylphosphonic acid, hexyl 4-(2-phenylprop-2-yl)phenyl ester, Caryophyllene, Coumarin, Delta-cadinene, Dotriacontane, Gamma-mourolen, Gamma-sitosterol, Germacrene D, Gitoxigenin, Hexacosane, Hexadeconoic acid, Hydrocoumarin, Methyl cis-1 1 ,14,17-icosatrienoate, Methyl linoleate, Methyl palmitate, Neophytadiene, N- hexatriacontane, n-tertacontane, N-tetracosane, N-tetratriacontane, N-triacontane, Phytol, Precocene I, Precocene II, Squalene, Stigmasterol, Stimasta-4,2,2-dien-3,P-ol and Tetracontane, Tetradecanoic acid.
[0026] Table 2 illustrates the list of compounds extracted by treating the plant material 120 using the ethanol solvent 170.
2H-chromen-2-one
3',4',5,6,7,8-hexamethoxyflavone
3,5-di-tert-buty!benzoic acid
3,7,1 1 ,15-tetram ethyl hexadec-2-en- 1 -ol
3-thujanol
4-tert-butyi-2,6-dimethylacetophenone
6-demethoxyageratochromene
6-vinyl-7-methoxy-2,2-dimethylchromene
9,12-octadecadienoic acid (Z,Z)-
All-trans-squalene
Alpha-benzopyrone
Alpha-caryophyllene
Alpha-linolenic acid
Alpha-octadecanoic acid
Alpha-tocopherol- -D-mannoside
Beta-sesquiphellandrene
Butylphosphonic acid, hexyl 4-(2-phenylprop-2-yl)phenyl ester
Caryophyllene
Coumarin
Delta-cadinene
Dotriacontane
Gamma-mourolen
Gamma-sitosterol
Germacrene D
·', Gitoxigenin
Hexacosane
Hexadeconoic acid
Hydrocoumarin
Methyl cis-11 , 14, 17-icosatrienoate
Methyl linoleate
Methyl palmitate
Neophytadiene
N-hexatriacontane
41 n-tertacontane
42 N-tetracosane
43 N-tetratriacontane
44 N-triacontane
45 Phytol
46 Precocene I
47 Precocene II
48 Squalene
49 Stigmasterol
50 Stimasta-4,2,2-dien-3, -ol
51 Tetracontane
52 Tetradecanoic acid
Table 2
[0027] The green colored solvent extract from ethanol/methanol/other solvents are removed using vacuum evaporation. Among the compounds of plants, Ageratum spp. four compounds, 9,12-octadecadienoic acid (Z,Z)-, Alpha-linolenic acid, Hexadeconoic acid and Hydrocoumarin are identified as 5 Alpha-reductase inhibitors. The 5 alpha reductase enzyme metabolizes the testosterone (male hormone) into dihydrotestosterone (DHT), which is known to induce scalp hair loss in man. The 5 alpha reductase inhibitors present in the extracts of Ageratum spp. can attach with 5 alpha reductase enzyme and prevent it to convert the testosterone into DHT. Thereby decrease and stop the hair loss.
[0028] Table 3 illustrates the list of four compounds identified as 5 Alpha reductase inhibitors present in both ethanol and methanol extracts of the hair growth product.
Table 3
[0029] The compounds obtained at both the ethanol solvent extraction process 140 and the methanol solvent extraction process 150 (and other solvent processes) are further pooled together in order to form the herbal extract 180 for simulating the hair growth. The green colored solvent extracts are separated and the ethanol/methanol/other solvents are removed using vacuum evaporation. Among the compounds of plants, Ageratum spp. six major compounds, N,N-bis(trimethylsilyl)-2- phenyl-7-(trifluoromethyl)quinolon-4-amine, 3',4',5,6,7,8-hexamethoxyflavone, Phytol, Precocene, Caryophyllene, Squalene are identified as common components present in both ethanol and methanol extracts of the hair growth product.
[0030] Table 4 illustrates the list of six major compounds identified as common components present in both ethanol and methanol extracts of the hair growth product.
Table 4
[0031] The herbal extract contains the above 5 alpha reductase inhibitors and other major compounds of plants, Aageratum spp. 1 10 in combination with an acceptable carrier or diluent can be further prepared into an herbal extract formulations 190 such as, aqueous (liquid), gel, oil or shampoo formulation for topical application.
[0032] The herbal extract of Ageratum spp. with the above mentioned compounds can be dissolved in the sterile distilled water (at 1-5 g/l) and the aqueous suspension
can be filtered (through 1 to 5 μ filter, pH adjusted to neutral) in order to form a liquid formulation 192 of the herbal extract. Similarly, the herbal extract is dissolved in vegetable oil/PG/PL and the suspension is filtered (through 1 to 5 μ filter) in order to form an oil formulation 194. The herbal extract can be dissolved in a small quantity of ethanol and filtered (through 1 to 5 μ filter) in order to form the gel formulation 96. The mixture can be mixed vigorously using mechanized homogenizer to get the uniform gel product. The herbal extract can be dissolved in an acceptable carrier or diluent in order to get the shampoo formulation 198. The mixture can be mixed vigorously using mechanized homogenizer to get the uniform shampoo product. The herbal extract formulation 190 disclosed herein can be utilized to effectively control the hair loss due to scenarios such as, but not limited to, genetic predisposition, endocrine disorders, medication, radiation, chemotherapy, exposure to chemicals, nutritional factors, generalized or local skin diseases, stress, child birth, Alopecia areata and mechanical damage, Trichotillomania, hair styling treatment, hair braids and weaves. The herbal extract formulation 190 prevents the cease of production of hair due to physiological phase changes such as, Anagen, Catagen and Telogen in humans.
[0033] FIG. 2 illustrates a high level flow chart of operations illustrating logical operational steps of a method 200 for preparing an herbal extract formulation 190 using herbaceous plants, Ageraium spp. 110, in accordance with the disclosed embodiments. Note that in FIGS. 1-2, identical or similar blocks are generally indicated by identical reference numerals. Initially, the plants, Ageratum spp. 1 10 with 60 to 90 days of age can be identified and the leaves and soft stems of the Ageratum spp. 1 10 can be sliced into pieces (approx. 1 cm size) 120, as illustrated at block 205. The sliced pieces 20 of the plants, Ageratum spp. 1 10 can be further shade dried at room temperature or dried at 45°C using a fluid flash dryer, as depicted at block 210. A mechanized pulverizing machine 130 can be employed to grind the dried plant slices 20 into coarse powder, as illustrated at block 215. The plant material can be further extracted using the ethanol and methanol solvents and other solvents 160 and 170 separately, as depicted at blocks 220 and 230. The solvent extraction process 140 and 150 described herein can be performed at a 1 :10 (WA/) ratio using a soxhlet apparatus. The green colored
solvents can be further extracted and separated by removing ethanol/methanol/other solvents 160 and 170 using a rotoevaporator, as illustrated at blocks 225 and 235.
[0034] The compounds obtained at both the ethanol solvent extraction process 140 and the methanol solvent extraction process 1 50 can be pooled together or separately in order to form the herbal extract 180 for simulating the hair growth, as depicted at block 240. As described earlier, six major compounds including N,N-bis(trimethylsilyl)-2- phenyl-7-(trifluoromethyl)quinolon-4-amine, S'^'.S /.S-hexamethoxyflavone, Phytol, Precocene, Caryophyllene, Squalene are identified as common marker components in the hair growth product. Further, four compounds, a-linolenic acid, 9, 12-octadecadienoic acid (Z,Z)-, Hexadeconoic acid and Hydrocoumarin are identified as 5 a-reductase inhibitors in the ethanol extract of Ageratum spp. and these compounds probably responsible for hair loss preventing activity of the hair growth product. As illustrated at block 245, the concentrated herbal extract 180 can be further formulated with an acceptable carrier or diluent in order to formulate as liquid, oil, gel or shampoo for topical application. The purified form of herbal extract 180 can be dissolved in the sterile distilled water (at 1-5 g/l) in order to filter the aqueous suspension (through 1 to 5 μ filter, pH adjusted to neutral), as illustrated at block 250. The concentrated material can be further added with acceptable carrier or diluent in order to form the aqueous (liquid) formulation 192 of the herbal extract, as illustrated at block 255.
[0035] Similarly, the herbal extract 180 can be dissolved in vegetable oil/PG/PL in order to filter the suspension (through 1 to 5 μ filter), as illustrated at block 260. The concentrated extract 180 can be further added with the acceptable carrier and diluent (e.g., coconut oil) in order to form the oil formulation 94, as depicted at block 265. The concentrated materia! 180 can be dissolved in a small quantity of ethanol in order to filter the suspension (through 1 to 5 μ filter), as illustrated at block 270. The concentrated materia! 180 can be further added with the acceptable carrier and diluent in order to form the gel formulation 196, as depicted at block 275. The mixture can be mixed vigorously using mechanized homogenizer to get the uniform gel product 196. The concentrated material 180 can be further added with the acceptable carrier and
diluent in order to form the shampoo formulation 198, as depicted at block 275. The mixture can be mixed vigorously using mechanized homogenizer to get the uniform shampoo product 198. Note that the aqueous (liquid), oil, gel and shampoo formulations 192, 194, 196 and 198 of the herbal extracts are packed separately in PP bottles aseptically. Such an herbal preparation using plants, Ageratum spp. can be utilized as an efficient hair care solution in a wide range of hair growth related problems of humans in a cost effective manner.
[0036] The clinical trials on the with respect to the formulations 192-198 have proved that the formulations do not have any adverse events and deviations. Under standard lab conditions, the formulations 192-198 did not indicated a potential for dermal irritation and/or allergic contact sensitization.
[0037] Three different formulations such as aqueous (liquid), gel and oil developed using the herbal preparation of Ageratum spp. were tested for hair growth promotion in animal studies using C57BL/6 mice model. The experimental design is as follow:
GroupDescription
Group-I Negative control
Group-ll Placebo - 1 (Gel excluding herbal extract)
Group-Ill Placebo - 2 (Aqueous excluding herbal extract)
Group-IV Placebo - 3 (Oil excluding herbal extract)
Group-V Formulation - 1 (Gel with herbal extract)
Group-VI Formulation - 2 (Aqueous with herbal extract)
Group-VII Formulation - 3 (Oil with herbal extract)
Group-VIII Standard Market Product
[0038] The hair growth potential of the given formulations was evaluated using C57BL/6 mice and for which, approval from ethical committee was obtained. Primary skin irritation test for all formulations was done for 48 hours. The hairs were removed from the mice using conventional method (Paraffin wax strip) and hair growth
formulations were applied in mice on regular intervals of 24 hours. The following are the observations made.
Colour change.
Raising of hair follicle.
Excision of skin for H & E staining.
Immuno- staining to differentiate the keratinocytes.
Hair density measurements.
[0039] Among the eight groups, Group I acted as a negative control and Group VIII acted as a positive control. The positive control group received (standard market product) as test compound according to the standard procedures. All the three formulations alone excluding the active principle were kept as Placebo (Group II, HI, and IV). Hair depilation was made by paraffin wax strips. All the test formulations were applied at 24 hours intervals and the animals were kept under observations on changes in skin colour. Since the chosen mice displayed change in the skin colour with reference to hair growth, the indication on skin colour implies the efficacy of the test formulations. It has been observed that both negative control and placebo groups displayed normal hair growth profile, whereas mice in the groups of V, VI, VII and VIII have displayed advancement in hair giowth pattern. The colouration from pink to grey and then to dark was significantly advanced in Group VII and it was comparable with Group VIII. Similarly, the H&E staining of sections also demonstrated the advancement in hair follicle regeneration and immunostaining has suggested the early keratinization in test formulations and standard market product treated mice,
[0040] Interestingly, the hair density was maximum in Group VIII, followed by V!! and V and the size of hair and hair bulb nature were also significant changed in the above Groups mice compared to negative control and Placebo treated mice. Among the three formulations (gel, aqueous and oil), the gel and oil formulations were more effective than the aqueous formulation. Although, the aqueous formulation induced localized hair growth profile, because of non-adherence to the skin, the expected results
were not obtained. Overall, the study suggested, that the gel and oil formulations displayed effective hair growth profile comparable to that of positive control, standard product.
[0041] Similarly, the 10% aqueous herbal extract prepared using Ageratum spp. was tested against dandruff causing fungal pathogens, Pityrosporum ovale and Pityrosporum folliculitis under in vitro condition by well diffusion technique. The experimental design is as follow:
Treatment Description
1 Sterile water - Negative control)
2 Ketaconazole (100 pg/ml) - Positive control
3 Herbai extract (10% @ 50 pi/well)
4 Herbal extract (10% @ 100 pi/well)
[0042] The agar plates were prepared and the dandruff pathogens, Pityrosporum ovale and Pityrosporum folliculitis were inoculated over the agar surface. Four wells were made using sterile cork borer and 10% aqueous herbal extract of A. conyzoides was' added at 50 and 100 pi in respective well. Commercial fungicide, Ketaconazole at 100 pg/ml (Positive control) and sterile water (Negative control) were also added in respective wells. The plates were incubated at room temperature for seven days and observed for the inhibition of fungal growth.
[0043] Prominent zone of inhibition of both the dandruff pathogens, P. ovale and P. folliculitis was observed around aqueous herbal extract of A. conyzoides at 50 and 100 pi added wells and 'it was higher than the commercial fungicide, Ketaconazole added well. No growth inhibition was recorded around sterile water added well. In summary, the study suggested that the aqueous herbal extract of A. conyzoides exhibited superior antifungal activity against the dandruff pathogens,. P. ovale and P. folliculitis than the commercial antidandruff agent, Ketaconazole.
[0044] It will be appreciated that variations of the above-disclosed and other features and functions, or alternatives thereof, may be desirably combined into many other different systems or applications. Also that various presently unforeseen or unanticipated alternatives, modifications, variations or improvements therein may be subsequently made by those skilled in the art which are also intended to be encompassed by the following claims.
Claims
1. An herbal preparation for stimulation using herbaceous plants, Ageratum spp., comprising:
at least one primary compound of a herbaceous plant, Ageratum spp. can be extracted using a common plant extraction approach (CPEA) wherein said at least one primary compound can be extracted using an ethanol solvent and a methanol solvent separately; and
an herbal formulation can be prepared by pooling said at least one primarycompound of said herbaceous plant, Ageratum spp. at said ethanol solvent and said methanol solvent in order to thereby obtain an herbal extract by adding an acceptable carrier for simulating follicles of hair wherein said herbal extract can be effectively used for hair growth and control of hair fall, dandruff and infections thereof.
2. The herbal preparation of claim 1 wherein said at least one primary compound comprises at least one of the following concentrated materials: N,N-bis(trimethy!silyl)-2- phenyl-7-(trifluoromethyl)quinolon-4-amine, 3',4',5,6,7,8-hexameth0xyflavone, Phytol, Precocene, Caryophyliene, Squalene, a-linolenic acid, 9,12-octadecadienoic acid (Z,Z)-, Hexadeconoic acid and Hydrocoumarin.
3. The herbal preparation of claim 1 wherein said methanol solvent extraction process extracts at least one of the following compounds: N,N-bis(trimethylsilyl)-2-phenyl-7- (trifluoromethyl)quinolon-4-amine, 1 -deoxy-d-mannitol, 15-hydroxypentadecanoic acid, 2-chromenone, 3',4',5,6,7,8-hexamethoxyflavone, 3,5-di-tert-butylbenzoic acid, 3,7,1 1 ,15-tetramethy!hexadec-2-en-1-ol, 4-tert-butyl-2,6-dimethylacetophenone, 6-vinyl- 7-methoxy-2,2-dimethylchromene, Anhydro-d-mannosan, Beta-Funebrene, Caryophyliene, Coumarin, Hexa-o-methylmyricitin, Hydrocoumarin, Linoleoyl chloride, Methyl cis-11 ,14,17-icosatrienoate, Methyl !inoieate, Neophytadien , p- Octylacetophenone, Phenol, 2,4,6-tris(1 ,1 -dimethyIethyl), Phytol, Precocene I and Squalene.
4. The herbal preparation of claim 1 wherein said ethanol solvent extraction process extracts at least one of the following compounds: N,N-bis(trimethylsilyl)-2-phenyl-7- (trifluoromethyl)quinolon-4-amine, (Z)-,Beta-farnesene, 1-(3,5-ditert-butyl-4- hydroxyphenyl)ethanone, 2-(1 ,3-benzodioxol-5-yl)-5-hydroxy-3,6,7,8-tetramethoxy-4h- chromen-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1 -benzopyran-4-one» 2,4,6-tri-tert-butylphenol, 2-chromanone, 2H-chromen-2-one, 3', 4', 5, Q, 7,8- hexamethoxyflavone, 3,5-di-tert-butylbenzoic acid, 3,7, 1 1 ,15-tetramethylhexadec-2-en- -οΙ, 3-thujanol, 4-tert-butyl-2,6-dimethylacetophenone, 6-demethoxyageratochromene, 6-vinyl-7-methoxy-2,2-dimethylchromene, 9,12-octadecadienoic acid (Z,Z)-, All-trans- squalene, Alpha-benzopyrone, Alpha-caryophyllene, Alpha-linolenic acid, Alpha- tocopherol-P-D-mannoside, Beta-sesquiphellandrene, Butylphosphonic acid, hexyl 4-(2- phenylprop-2-yl)pheny! ester, Caryophyllene, Coumarin, Delta-cadinene, Dotriacontane, Gamma-mourolen, Gamma-sitosterol, Germacrene D, Gitoxigenin, Hexacosane, Hexadeconoic acid, Hydrocoumarin, Methyl cis- , 4, 17-icosatrienoate, Methyl linoleate, Methyl palmitate, Neophytadiene, N-hexatriacontane, n-tertacontane, N- tetracosane, N-tetratriacontane, N-triacontane, Phytol, Precocehe I, Precocene II, Squalene, Stigmasterol, Stimasta-4,2,2-dien-3, -ol, and Tetracontane.
5. The herbal preparation of claim 1 wherein said herbal extract can be dissolved in the sterile Distilled water (at 1 -5 g/l) and the aqueous suspension can be filtered (through 1 to 5 μ filter, pH adjusted to neutral) in order to form a liquid formulation of said herbal extract.
6. The herbal preparation of claim 1 wherein said herbal extract is dissolved in the vegetable oil or PG/PL and the suspension is filtered (through 1 to 5 μ filter) in order to form an oil formulation of said herbal extract.
7. The herbal preparation of claim 1 wherein said herbal extract can be dissolved in a small quantity of ethanol in order to form a gel formulation of said herbal extract.
8. The herbal preparation of claim 1 wherein said acceptable carrier comprises a diluent.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3384CH2012 | 2012-08-16 | ||
| PCT/IN2013/000502 WO2014027370A1 (en) | 2012-08-16 | 2013-08-14 | Herbal preparation for stimulation of hair growth, control of hair fall, dandruff and infections thereof using ageratum spp. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2885054A1 true EP2885054A1 (en) | 2015-06-24 |
Family
ID=50685444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP13879457.3A Withdrawn EP2885054A1 (en) | 2012-08-16 | 2013-08-14 | Herbal preparation for stimulation of hair growth, control of hair fall, dandruff and infections thereof using ageratum spp. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2885054A1 (en) |
| KR (1) | KR20150042244A (en) |
| AU (1) | AU2013303762B2 (en) |
| CA (1) | CA2884774A1 (en) |
| NZ (1) | NZ705751A (en) |
| SG (2) | SG10201701217SA (en) |
| WO (1) | WO2014027370A1 (en) |
| ZA (1) | ZA201501443B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9452129B1 (en) * | 2015-10-06 | 2016-09-27 | Indfrag Biosciences Inc. | Composition of hair oil for stimulation of hair growth, control of hairfall, dandruff and infections thereof |
| US10543157B2 (en) | 2016-04-29 | 2020-01-28 | The Procter And Gamble Company | Method of treating a hair disorder with N-hydroxypyridinones |
| US9949915B2 (en) | 2016-06-10 | 2018-04-24 | Clarity Cosmetics Inc. | Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use |
| US10736398B2 (en) | 2016-12-12 | 2020-08-11 | The Procter And Gamble Company | Apparatus and method for pulling a strand of hair |
| CN111423300B (en) * | 2019-01-10 | 2023-02-28 | 四川弘合生物科技有限公司 | Preparation method of beta elemene |
| WO2021030717A1 (en) * | 2019-08-14 | 2021-02-18 | Ge Nutrients, Inc. | Herbal preparation for stimulation of hair growth, control of hair fall, dandruff and infections thereof using ageratum spp. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09295919A (en) * | 1996-05-07 | 1997-11-18 | Res Inst For Prod Dev | Hair restoring agent |
| JP2005008611A (en) * | 2003-06-18 | 2005-01-13 | Yoshimasa Kojima | Skin external preparation |
| JP2006062988A (en) * | 2004-08-25 | 2006-03-09 | Mikimoto Pharmaceut Co Ltd | Elastase activity inhibitor |
| JP2006062990A (en) * | 2004-08-25 | 2006-03-09 | Mikimoto Pharmaceut Co Ltd | Restoration agent for ultraviolet damage to cell |
-
2013
- 2013-08-14 SG SG10201701217SA patent/SG10201701217SA/en unknown
- 2013-08-14 AU AU2013303762A patent/AU2013303762B2/en not_active Ceased
- 2013-08-14 CA CA2884774A patent/CA2884774A1/en not_active Abandoned
- 2013-08-14 WO PCT/IN2013/000502 patent/WO2014027370A1/en not_active Ceased
- 2013-08-14 NZ NZ705751A patent/NZ705751A/en not_active IP Right Cessation
- 2013-08-14 EP EP13879457.3A patent/EP2885054A1/en not_active Withdrawn
- 2013-08-14 SG SG11201501912PA patent/SG11201501912PA/en unknown
- 2013-08-14 KR KR20157006030A patent/KR20150042244A/en not_active Ceased
-
2015
- 2015-03-03 ZA ZA2015/01443A patent/ZA201501443B/en unknown
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2014027370A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2884774A1 (en) | 2014-02-20 |
| SG10201701217SA (en) | 2017-03-30 |
| WO2014027370A1 (en) | 2014-02-20 |
| AU2013303762A1 (en) | 2015-03-19 |
| NZ705751A (en) | 2018-04-27 |
| SG11201501912PA (en) | 2015-05-28 |
| KR20150042244A (en) | 2015-04-20 |
| AU2013303762B2 (en) | 2018-05-31 |
| ZA201501443B (en) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111202708B (en) | Cosmetic composition for improving skin comprising plant cell complex culture | |
| AU2013303762B2 (en) | Herbal preparation for stimulation of hair growth, control of hair fall, dandruff and infections thereof using Ageratum spp. | |
| KR101549299B1 (en) | Anti-aging and Anti-inflammation and Anti-oxidation cosmetic composition including Lotus Plant Placenta Cell Cultures Extracts | |
| KR101533947B1 (en) | Anti-aging and Anti-inflammation and Anti-oxidation cosmetic composition including Paeonia suffruticosa Plant Placenta Cell Cultures Extracts | |
| KR102833257B1 (en) | Kapok tree flower extract and cosmetic, pharmaceutical or dermatological compositions containing the same | |
| JPH0761915A (en) | External agent for skin | |
| WO2005034894A1 (en) | Hair growth stimulant composition | |
| KR102032873B1 (en) | Antioxidant and moisturizing cosmetic composition | |
| KR101561408B1 (en) | Anti-aging and Anti-inflammation and Anti-oxidation cosmetic composition including Peony Plant Placenta Cell Cultures Extracts | |
| KR101533213B1 (en) | Anti-aging and Anti-inflammation and Anti-oxidation cosmetic composition including Anemone Plant Placenta Cell Cultures Extracts | |
| KR101143717B1 (en) | Composition for Skin External Application Comprising Extract of Nelumbo Nucifera Callus | |
| KR101173993B1 (en) | An anti-oxidant, anti-inflammatory or anti-allergic composition for cosmetics comprising essentially aplysia kurodai ferments as an effective component and production method of the same | |
| KR101533217B1 (en) | Anti-aging and Anti-inflammation and Anti-oxidation cosmetic composition including Nymphaea tetragona Plant Placenta Cell Cultures Extracts | |
| WO2014173635A1 (en) | A topical composition for hair growth | |
| KR20100011176A (en) | Natural and oriental herbs complex with anti-hairloss and hair growth stimulating effects | |
| KR20160062235A (en) | Cosmetic composition for whitening skin comprising mixed extract of Cudrania tricuspidata leaf and Morus alba leaf as effective component | |
| KR20190067287A (en) | Anti-aging and anti-allergic cosmetic compositon comprising the extract of the flower, root, callus and seed of Hibiscus syriacus L. as an active ingredient and preparation method of the same | |
| KR101533214B1 (en) | Anti-aging and Anti-inflammation and Anti-oxidation cosmetic composition including epatica asiatica Nakai Ranunculales Plant Placenta Cell Cultures Extracts | |
| JP2015193550A (en) | DNA damage inhibitor of hair follicle keratinocyte stem cells | |
| KR100822264B1 (en) | Hair cosmetic composition containing anti-dandruff substance isolated from ginkgo biloba and pine needles | |
| CN113164543A (en) | Zingiber zerumbet extract for resisting dandruff | |
| US8986752B1 (en) | Skin care treatment | |
| KR20100000900A (en) | Cosmetic composition for protecting the skin comprising the plant extracts | |
| PL247900B1 (en) | Hair shampoo and method of producing shampoo | |
| JP2001354523A (en) | Hair restorer composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20150310 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20160301 |